BusinessAkari Therapeutics Expands Clinical and Regulatory Teams with Industry VeteransBy Nasdaq OMXJan 4, 2017, 12:00 PM UTC
BusinessAkari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNHBy Nasdaq OMXJan 3, 2017, 12:01 PM UTC
BusinessAkari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNHBy Nasdaq OMXJan 3, 2017, 12:01 PM UTC
BusinessAkari Therapeutics Announces Corporate Update with New Positive Clinical Data and a New Pipeline of Tick Derived and Engineered ProteinsBy Nasdaq OMXDec 5, 2016, 12:00 PM UTC
BusinessAkari Therapeutics to Attend Upcoming Investor Conferences In NovemberBy Nasdaq OMXNov 11, 2016, 12:00 PM UTC
BusinessAkari Therapeutics to Present Abstract on Potential Once Weekly PAS-Coversin at the 58th Annual Meeting of the American Society of HematologyBy Nasdaq OMXNov 3, 2016, 12:01 PM UTC
BusinessAkari Therapeutics to Present at Upcoming Investor Conferences on September 27 and 28 in New York CityBy Nasdaq OMXSep 16, 2016, 4:18 PM UTC
BusinessAkari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal HemoglobinuriaBy Nasdaq OMXSep 12, 2016, 11:15 AM UTC
